CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cabaletta Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.48+0.07 (+4.96%)
Close on Oct 19, 2026
- Market cap
- $223.72M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -26.9% | -127.0% | |
| Return on assets | – | -26.0% | -95.9% | |
| Current ratio | – | 21.92 | 2.77 | |
| Interest coverage | – | – | -85.9× | |
| Diluted shares | – | – | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cabaletta Bio generated $353.34M from operations and spent $7.75M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$353.34M
Used
$7.75M
Capital expenditure$7.75M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$167.86M
- Cash generatingOperating cash flow above zero-$131.08M
- Return on assets improvedROA up on the prior year-45.7% → -90.7%
- Earnings backed by cashOperating cash flow above net income-$131.08M vs -$167.86M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.15 → 2.77
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –